These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21167115)

  • 21. Nanomedicine against multidrug resistance in cancer treatment.
    Gao J; Feng SS; Guo Y
    Nanomedicine (Lond); 2012 Apr; 7(4):465-8. PubMed ID: 22471716
    [No Abstract]   [Full Text] [Related]  

  • 22. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP; Hsu KS; Kuo CC; Chang CY; Chang JY
    J Pharmacol Exp Ther; 2007 Oct; 323(1):398-405. PubMed ID: 17660383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obinutuzumab in multidrug-resistant hairy cell leukemia.
    Bohn JP; Willenbacher E; Steurer M
    Ann Hematol; 2016 Jan; 95(2):351-2. PubMed ID: 26446506
    [No Abstract]   [Full Text] [Related]  

  • 24. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
    Manna SK; Gangadharan C
    Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isomeric N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent P-glycoprotein (Pgp)-dependent multidrug resistance (MDR) inhibitors.
    Teodori E; Martelli C; Salerno M; Darghal N; Dei S; Garnier-Suillerot A; Gualtieri F; Manetti D; Scapecchi S; Romanelli MN
    J Med Chem; 2007 Feb; 50(4):599-602. PubMed ID: 17256837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-(3,4,5-Trimethoxyphenyl)-1-oxo-2-propene: a novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity.
    Das U; Kawase M; Sakagami H; Ideo A; Shimada J; Molnár J; Baráth Z; Bata Z; Dimmock JR
    Bioorg Med Chem; 2007 May; 15(10):3373-80. PubMed ID: 17383883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flavonoid dimers as bivalent modulators for P-glycoprotein-based multidrug resistance: synthetic apigenin homodimers linked with defined-length poly(ethylene glycol) spacers increase drug retention and enhance chemosensitivity in resistant cancer cells.
    Chan KF; Zhao Y; Burkett BA; Wong IL; Chow LM; Chan TH
    J Med Chem; 2006 Nov; 49(23):6742-59. PubMed ID: 17154505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
    Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
    J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redox-sensitive signaling factors as a novel molecular targets for cancer therapy.
    Pennington JD; Wang TJ; Nguyen P; Sun L; Bisht K; Smart D; Gius D
    Drug Resist Updat; 2005 Oct; 8(5):322-30. PubMed ID: 16230045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
    Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P
    In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study on the effects of tetramethylpyrazine on tumor cells: survey and prospects].
    Wang X; Chen X
    Zhongguo Zhong Yao Za Zhi; 2003 Apr; 28(4):295-8. PubMed ID: 15171214
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug resistance in hematologic malignancies.
    Dalton W
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):267-8. PubMed ID: 16166998
    [No Abstract]   [Full Text] [Related]  

  • 35. Reversal effect of BM-cyclin 1 on multidrug resistance in C-A120 cells.
    Wang L; Sun J; Li YQ; Chen ZS; Akiyama S; Xian LJ
    Anticancer Drugs; 2007 Oct; 18(9):1015-21. PubMed ID: 17704651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cholesterol metabolism and tumor cell proliferation.
    Coleman PS; Chen LC; Sepp-Lorenzino L
    Subcell Biochem; 1997; 28():363-435. PubMed ID: 9090301
    [No Abstract]   [Full Text] [Related]  

  • 37. A price to pay for tumor regression.
    Bernards R
    Cell Res; 2015 Jul; 25(7):763-4. PubMed ID: 25895608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dodging a dogma: is treating beyond progression beneficial?
    Naing A; Kurzrock R
    Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
    [No Abstract]   [Full Text] [Related]  

  • 39. Tumor chemosensitization by physical exercise? Insights from an anidmal model.
    Vaccarezza M; Vitale M
    Future Oncol; 2015; 11(6):885-7. PubMed ID: 25760967
    [No Abstract]   [Full Text] [Related]  

  • 40. Optimization of an in vitro chemotherapy to avoid resistant tumours.
    Carrère C
    J Theor Biol; 2017 Jan; 413():24-33. PubMed ID: 27864095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.